Microneedle and mucosal delivery of influenza vaccines.
Microneedle and mucosal delivery of influenza vaccines.
复制标题
DOI：
10.1586/erv.12.25
复制
发表时间：
2012-05
影响因子：
6.2
通讯作者：
Kim YC
中科院分区：
文献类型：
--
作者：
Kang SM;Song JM;Kim YC
近年来，随着大流行性流感的威胁和其他公共卫生需求，肌内免疫以外的替代疫苗接种方法受到了极大的关注。皮肤和粘膜表面是有吸引力的部位，可能是因为疫苗递送的非侵入性途径和独特的免疫应答。使用显微注射系统的皮内疫苗（BD Soluvia）和鼻内疫苗（FluMist）已获得许可。作为一种新的疫苗接种方法，固体微针已经使用可能适合于自我给药的简单装置开发出来。由于包衣微针流感疫苗是以固态给药，因此开发保持流感疫苗稳定性的制剂是需要考虑的重要问题。可销售的微针装置和临床试验仍有待开发。其他替代的粘膜途径，如口服和鼻内递送系统也有吸引力的诱导交叉保护性粘膜免疫，但有效的非活粘膜疫苗仍有待开发。
In recent years with the threat of pandemic influenza and other public health needs, alternative vaccination methods other than intramuscular immunization have received great attention. The skin and mucosal surfaces are attractive sites probably because of both non-invasive access to the vaccine delivery and unique immunological responses. Intradermal vaccines using a microinjection system (BD Soluvia) and intranasal vaccines (FluMist) are licensed. As a new vaccination method, solid microneedles have been developed using a simple device that may be suitable for self-administration. Because coated micorneedle influenza vaccines are administered in the solid state, developing formulations maintaining the stability of influenza vaccines is an important issue to be considered. Marketable microneedle devices and clinical trials remain to be developed. Other alternative mucosal routes such as oral and intranasal delivery systems are also attractive for inducing cross protective mucosal immunity but effective non-live mucosal vaccines remain to be developed.
登录
查看更多内容
影响因子：
5.5
作者：
Beyer, WEP;Palache, AM;Osterhaus, ADME
通讯作者：
Osterhaus, ADME
影响因子：
2.9
作者：
Breau, LM;McGrath, PJ;Reid, GJ
通讯作者：
Reid, GJ
影响因子：
5.4
作者：
Chen, DX;Periwal, SB;Payne, LG
通讯作者：
Payne, LG
影响因子：
4.1
作者：
Avtushenko, SS;Sorokin, EM;Naichin, AN
通讯作者：
Naichin, AN
影响因子：
5.5
作者：
Belshe, Robert B.;Newman, Frances K.;Frey, Sharon E.
通讯作者：
Frey, Sharon E.